Drugs Made In America Acquisition Corp. Prices $200M IPO
Deal News | Jan 27, 2025 | EIN
Drugs Made In America Acquisition Corp., a blank check company incorporated in the Cayman Islands, has announced the pricing of its Initial Public Offering (IPO) of 20,000,000 units at $10.00 per unit, raising $200 million. The units will trade on the Nasdaq Global Market under the ticker symbol DMAAU starting January 28, 2025. Each unit consists of one ordinary share and a right to receive one-eighth of an ordinary share upon consummation of a business combination. The offering, expected to close on January 29, 2025, has been managed by Clear Street as the sole book-runner, with Loeb & Loeb LLP serving as legal counsel. The company plans to focus its acquisition efforts in the pharmaceutical industry to bolster the U.S. medical supply chain by investing in domestic manufacturing technologies. The IPO registration was filed with the SEC and recent amendments were made effective, ensuring compliance and readiness for market entry.
Sectors
- Pharmaceutical
- Finance
- Legal Services
Geography
- United States – The company's focus is on the U.S. pharmaceutical supply chain, and the IPO will take place on the Nasdaq stock market in the United States.
- Cayman Islands – Drugs Made In America Acquisition Corp. is incorporated in the Cayman Islands, highlighting its global registration and operational strategy.
Industry
- Pharmaceutical – The industry focus for Drugs Made In America Acquisition Corp. is the pharmaceutical sector where they aim to invest and strengthen domestic production capabilities.
- Finance – The Initial Public Offering (IPO) of Drugs Made In America Acquisition Corp. involves considerable financial services, underwriting, and compliance efforts typical of high-level financial transactions.
- Legal Services – Legal advisors such as Loeb & Loeb LLP and Winston & Strawn LLP are involved in counsel for the company and underwriting, respectively, showing the importance of legal compliance and structuring in this transaction.
Financials
- $200,000,000 – The total expected proceeds from the initial public offering of 20,000,000 units at $10.00 per unit.
- 3,000,000 units – An additional number of units that can be purchased by the underwriter within 45 days to cover over-allotments.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Drugs Made In America Acquisition Corp. | Target | Company | A blank check company focusing on investments in the pharmaceutical sector to strengthen the U.S. supply chain. |
| Clear Street | Underwriter | Company | Acts as the sole book-running manager for the $200 million IPO of Drugs Made In America Acquisition Corp. |
| Loeb & Loeb LLP | Legal Advisor | Company | Serves as legal counsel to Drugs Made In America Acquisition Corp. for the IPO. |
| Winston & Strawn LLP | Legal Advisor to Underwriter | Company | Provides legal counsel to the underwriter, Clear Street. |
| Securities and Exchange Commission (SEC) | Regulator | Government | The government agency overseeing the registration and compliance of the securities offering. |